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The remarkable regenerative capacity of the liver is unique amongst solid organs, and 
has captivated the human imagination since antiquity: in Greek mythology the Titan Prometheus 
is chained for eternity, sentenced to have his liver repeatedly devoured by an eagle, only to 
have it regrow in place for repeated torment. The ability to leverage the organ’s regenerative 
capacity has facilitated progressively more aggressive approaches to previously considered 
unresectable hepatic tumors. In the management of colorectal liver metastases (CRLM) in 
particular, the paradigm has shifted from previously unresectable criteria, to the standard-of-
care being surgical resection of metastases as long as there remains sufficient future liver 
remnant (FLR), typically 20-30% of the healthy native liver [1]. Over the last two decades 
advances in liver surgery have pushed the boundary of resectability by incorporating vascular 
modulation such as portal venous ligation (PVL), embolization (PVE), and two-stage 
hepatectomies (TSH) to clear the FLR of invasive disease. 
 In 2007 a German surgeon, Prof. HJ Schlitt serendipitously discovered the synergistic 
effect of parenchymal transection and deportalization, which resulted in accelerated hypertrophy 
of the remnant liver: During the course of a right trisectionectomy for perihilar 
cholangiocarcinoma, Prof. Schlitt aborted the procedure after having ligated the right portal vein 
due to concern for insufficient FLR. Astoundingly, just a week after this procedure, the left-
lateral section was discovered to have nearly doubled in size. This allowed the completion 
hepatectomy just eight days after the initial surgery. This concept of parenchymal transection 
and deportalization became known as Associating Liver Partition and Portal Vein Ligation for 
Staged Hepatectomy (ALPPS) [2]. The inaugural description of accumulated experience with 
ALPPS in German clinics was presented four years later at the congress of the European 
African-Hepato-Pancreato-Biliary Association to a captivated audience in Capetown, South 
Africa , and the first 25 cases were published a year later [3]. At that time the HPB community 
reverberated with intrigue and boisterous enthusiasm as well as skepticism [4–6]. It is no 
 
 
overstatement to suggest that in the decade since first performed, ALPPS remains one of the 
most continuously evolving and controversial HPB procedures in the literature, with a distinct 
demarcation on either side of the Atlantic [7]. Yet out of the nascent first descriptions and rapid 
adoption, robust data has begun to accumulate helping to guide the experienced liver surgeon 
on when and if to utilize ALPPS. Here the evolution of ALPPS is reviewed, and as the procedure 
enters its thirteenth year of existence, we highlight critical lessons with a focus on the use of 
ALPPS for CRLM. 
Early adoption, modifications, and refinement of indications: 
 Soon after the first description of ALPPS, the procedure was adopted quickly, 
simultaneously being employed for a number of indications [8–10]. As a result the first described 
series of ALPPS were accompanied by alarming rates of perioperative morbidity and 90 day 
mortalities as high as 48% depending on the indication [9–11]. Not surprisingly there was a 
recoil against the procedure, due to what some called “innovation for innovation’s sake” [12]. 
Indeed, a close evaluation of ALPPS cases compiled in the international registry found a misuse 
of the procedure, with an unacceptably high number of cases being performed in patients who 
likely did not have an indication for a two-stage procedure [13]. It was readily apparent that 
ALPPS was similar to a zero-sum game; improved resectability and hypertrophy had to be 
counterbalanced with increased perioperative morbidity, and a careful assessment during 
interstage to decide if and when to proceed to completion resection [14–16]. 
 In order to address these early poor outcomes, surgeons developed modifications to the 
ALPPS procedure, attempting to mitigate a prolonged, invasive stage I procedure [17,18]. To 
this goal partial ALPPS was developed, offering comparable hypertrophic benefit to the classical 
ALPPS when transection occurs through at least 50% of the liver parenchyma, and with 
considerably less morbidity and minimal perioperative mortality [19,20]. Similarly, mini ALPPS 
combines a limited parenchymal transection paradigm, with minimal dissection of the porta 
hepatis by utilization of an intraoperative PVE [17]. One step beyond, tourniquet ALPPS spares 
 
 
parenchymal transection altogether, and instead drives hepatocyte stimulation through 
application of a vertical tourniquet through the future transection plane [21,22]. When combined 
with PVE, tourniquet ALPPS has been successfully applied to a variety of tumors including 
primary liver malignancies [23]. 
Additionally, descriptions of minimally invasive approaches to stage I through 
laparoscopic or robotic assisted procedures have been reported [24–26]. Encouragingly, the 
experience from São Paulo and others has demonstrated that laparoscopic ALPPS can be 
performed with excellent perioperative morbidity, mortality, and improved length-of-stay 
compared to classical ALPPS [27,28]. 
Anatomically, critical pitfalls in respecting hepatic inflow and outflow have amassed; 
preservation of the middle hepatic vein and section 3 venous drainage to maintain adequate 
outflow, careful interrogation of aberrant hepatic arterial anatomy, and careful interrogation of 
biliary anatomy to prevent injury to the segmental bile ducts during dissection, which can result 
in bile leaks and interstage sepsis [29]. 
Perhaps the greatest advances in mitigating poor outcomes from the ALPPS procedure 
has been the improvement in preoperative and interstage decision making. When first 
inaugurated, ALPPS was widely applied to various histologies, including intrahepatic 
cholangiocarcinoma (CCA), perihilar CCA, hepatocellular carcinoma, and CRLM, yet with little 
consideration for underlying liver disease, portal hypertension, or chemotherapy induced hepatic 
injury.  
The most common cause of postoperative mortality following ALPPS is post-stage II 
hepatic failure [30] To guide decision making prior to stage II, risk models have been developed 
and validated [31,32]. During interstage, an elevation in serum creatinine or total bilirubin have 
been linked to hepatic failure and mortality. Similarly post-stage I complications of Clavien-
Dindo class 3b or higher and an elevated pre-stage I risk score increase the risk of post-stage II 
mortality [33]. The available pre-stage I and pre-stage II risk scores should be utilized by all 
 
 
practitioners of ALPPS in order to guide improvement in surgical quality and refinement of the 
risk scoring with added experience. 
Mechanisms of Hypertrophy, Assessment of Hepatic Function, and Effects on Oncologic 
Outcome: 
 Dissimilar from ALPPS, following PVE it has been shown that hepatic volumetric growth 
may in some cases lag behind increased hepatic function [34]. Furthermore, in both ALPPS and 
PVE hepatic volume increase has been demonstrated to be a poor surrogate of increased 
hepatic function [35,36]. Mechanistically, preclinical rodent models of ALPPS have elucidated 
soluble factors IL6, TNFα and transcriptional regulation of phospho-STAT3 and YAP amongst 
others as drivers of hypertrophy with limited correlation with resected human tissue [37,38]. 
However, definitive mechanisms of what separated ALPPS from PVE alone remain elusive, and 
basic science in understanding the cellular mechanisms are an unmet need in the literature [29]. 
Fortunately, in the absence of biomarkers, hepatic scintigraphy has emerged as an adjunct for 
assessing adequate liver function. Serenari et al. recently demonstrated the use of single 
photon emission computed tomography (SPECT) utilizing 99mTc-mebrofenin can reliably 
segregate patients who demonstrate adequate hepatic function within the FLR (>15% of total 
counts) from those at risk of post-stage II hepatic failure [39]. Coupled with established risk 
scoring, SPECT imaging may aid in decision making regarding safety of undertaking stage II. 
 Some opponents of the ALPPS approach raise the concern of increased oncologic 
virulence by unleashing the rapid hypertrophy observed after ALPPS. Indeed some early reports 
highlighted rapid recurrence in cohorts of patients undergoing ALPPS [40]. However human 
observations and preclinical models have failed to demonstrate any difference in tumor 
stimulation between ALPPS or PVL/PVE [41]. Furthermore, histologic and immunohistochemical 
analyses of resected specimens following ALPPS and partial hepatectomy demonstrated no 
statistically significant difference in vascular invasion, proliferation, apoptosis, or recruitment of 
cancer associated fibroblasts [42]. While these studies remain limited by a lack of understanding 
of hypertrophic pathways and potential synergy across disparate oncologic drivers for different 
 
 
tumor histologies, to date no data has demonstrated that ALPPS uncovers more aggressive 
tumor biology compared to alternatives such as PVE. 
ALPPS for CRLM:  
 Colorectal cancer is the third most common malignancy worldwide, and 50% of patients 
present with or eventually develop hepatic metastases. Robust data has supported the 
oncologic benefit of CRLM resection and centers have even begun to explore the benefit of 
local treatment through total hepatectomy and transplantation in selected patients [43,44]. 
Analysis of the international ALPPS registry has shown CRLM as the best indication for 
applying ALPPS in patients with insufficient FLR [13]. Not surprisingly, this population is typically 
younger, has normal portal venous pressure and without underlying liver disease. However, 
careful multidisciplinary decision making, patient selection, and neoadjuvant therapeutic 
approach must be employed to navigate patients with borderline resectable CRLM to curative 
intent resection. 
Given the opportunity to downstage CRLM with increasingly more effective systemic 
regimens, patients should be given the trial of neoadjuvant chemotherapy in an attempt to 
preserve hepatic parenchyma, understand the tumor's biology, and potentially obviate the need 
for more radical surgery [45]. Furthermore, patients who progress radiographically or 
biochemically while on systemic therapy portend a poor prognosis despite resection, with a 
propensity for recurrence after surgery [46]. Extensive two stage procedures in this population 
should be approached with caution if not avoided. Most patients who present with liver-confined 
stage IV CRC do so synchronously with a primary lesion [47]. Patients who present with 
symptomatic primary lesions, either due to hemorrhage or obstruction should have the primary 
disease addressed. Similarly, patients with obstructing rectal adenocarcinoma may be initially 
treated with combination multimodal therapy for control of primary disease. However, a liver-first 
approach, after neoadjuvant therapy, in the case of asymptomatic primary lesions can yield 
improved outcomes by avoiding post-colectomy complications which obviate systemic therapy 
 
 
and result in loss of resectability for hepatic disease compared to colon-first approach [48]. A 
third alternative is synchronous resection, however, given the potential postoperative morbidity 
and increased mortality associated with colectomy and hepatectomy, it is not advisable to 
pursue synchronous primary resection and ALPPS [49,50]. 
A review of the International ALPPS Registry shows perioperative morbidity and 
mortality to be in keeping with other major hepatectomies when performed for CRLM [30]. 
Furthermore, reports from high volume centers demonstrate a 3-year survival of 50% and 
disease-free-survival of 13%, and importantly quality-of-life metrics in patients who underwent 
ALPPS were similar to the general population, demonstrating the ability of ALPPS to deliver 
disease control while returning patients to meaningful daily lives [51]. Still, early comparisons 
between ALPPS and TSH yielded discordant conclusions with some reports demonstrating 
worse intermediate survival with ALPPS compared to TSH, while others demonstrating parity 
between the two approaches [22,52,53]. More recently, completion of the first randomized 
control trial for patients with unresectable CRLM and FLR<30% has allowed the most adequate 
head-to-head comparison to date. 
The LIGRO trial was a scandanavian based randomized clinical trial which enrolled 100 
patients to ALPPS or TSH with the option of rescue ALPPS in the PVE group. The primary end-
point of the study was to evaluate resectability following vascular modulation in patients with 
colorectal liver metastases and insufficient future liver remnant. The first report from the trial 
demonstrated a positive result, with resection rates in the ALPPS arm compared to the PVE arm 
of 92% and 57% respectively (p<0.0001) [54] (Figure 1). Additionally, of the 21 patients that 
failed to attain sufficient hypertrophy following PVE, 57% were able to undergo salvage ALPPS 
and became resectable.  
It is important to note that the PVE methodology was not standardized across 
institutions, and the 57% resectability following PVE is low compared to contemporary reports 
which have demonstrated rates above 85% following PVE [55,56]. Nonetheless, postoperative 
 
 
morbi-mortality was similar between the two groups, and there was a trend towards improved 
R0 resection rate (R0 RR) in the ALPPS group compared to PVE [R0 RR: ALPPS 77% (34/44) 
vs PVE 57% (16/28) P = 0.11] [54]. This is in keeping with results from the European REBIRTH 
RCT, which demonstrated a 92.3% vs. 66.6% resection rate following radio-frequency ablation 
ALPPS and PVE respectively in patients with primary or secondary liver malignancy and 
insufficient FLR [57]. Furthermore, recurrence in the LIGRO trial after ALPPS was similar to 
TSH, with 7/13 patients who underwent ALPPS and 6/11 patients who underwent PVE and TSH 
experiencing recurrence of disease within a year [58].  
The most interesting result of the LIGRO trial was the finding of improved survival in the 
ALPPS group compared to the TSH group. With a median follow up of 36 months, ALPPS 
demonstrated an estimated median survival of 46 months compared to just 26 months for 
patients randomized to TSH (p=0.028) (Figure 1) [59]. Furthermore, at the first postoperative 
follow-up 77% of patients in the ALPPS group were assessed as tumor-free compared to 57% 
of patients randomized to the TSH group (p.0.028) [59]. Taken together, these results provide 
the strongest evidence and support the application of ALPPS for patients with CRLM. 
Conclusions: 
 ALPPS remains a critical tool in the armamentarium liver surgeons  which must be 
deployed with careful consideration and with the application of evidenced based risk-
stratification to ensure the best outcome for patients. Perioperative morbi-mortality have 
improved to be comparable with other major hepatectomy approaches such as TSH, and a 
recently reported randomized trial demonstrated improved survival for patients treated with 
ALPPS compared to TSH. The LIGRO trial, while the strongest evidence to date in support of 
ALPPS for surgical control of colorectal liver metastases with insufficient future liver remnant, 
should be replicated in future clinical trials in order to validate these findings in other indications 




● ALPPS has demonstrated excellent ability to achieve resectability compared to PVE and 
TSH in patients with CRLM and insufficient FLR. 
● Outcomes with ALPPS for CRLM have improved and are comparable to other major 
hepatectomies. 
● There is no evidence that the enhanced hypertrophy generated by ALPPS is 
oncologically inferior to techniques such as PVE or PVL. 
● ALPPS is a single tool in a broader armamentarium that should not be overused or 
misused.  
● Patient's CRC biology should be considered when considering surgical intervention; poor 
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To the Editors and Reviewers, 
Thank you for the opportunity to revise our work detailing recent advances utilizing the ALPPS 
technique for CRLM. We have addressed all comments and suggestions and present the 




Senior Editor: The review was reviewed by 2 expert reviewers and we all agree that this is a 
nice review which requires some minor modifications, as indicated below. 
I would like to write some editorial comments; 
Please keep authors as indicated in the title page (Hernandez-Alejandro, Ruffolo, Alikhanov, 
Bjornsson, Torres, Serrablo). Title page and what was entered in the submission system were 
different. 
We are welcome Dr. ********** to be the joint First Author. 
However, please omit Dr. ************ since he was not a part of the original invitation and he 
already has 3 other publications/ contribution in the special issue. 
Please keep highlights 125 characters per bullet.  
Thank you, we have corrected the manuscript, title, and authors to reflect the directions 
of the senior editor. 
------------------------------------------------------------------------------------------------------------------------------- 
Reviewer #1: The authors present a comprehensive review entitled "ALLPS as a teenager: 
maturation of technique and best practice for colorectal liver metastases". The manuscript 
covers important topics including refinement and modifications of indications, technical issues of 
the procedure, mechanisms of hypertrophy, and special considerations of ALPPS for colorectal 
liver metastases (CRLM). The paper is accompanied by one illustrative figure and 50 relevant 
references are quoted. Although the paper is well-written, it needs following modifications: 
1. The focus of this review article should be on CRLM. The authors spend a lot of effort in 
describing the evolution of ALLPS and its application to other indications such as HCC and 
biliary tumors (page 5) as well as mechanisms of hypertrophy and assessment of hepatic 
function. Only one paragraph (ALLPS for CRLM) is purely designated to the special aspects of 
CRLM. If the word count of this section is taken into account, the word count of the CRLM 
paragraph represents 18-20% of the total manuscript text word count. The authors should 
explain when liver-first and when primary-first approach needs to considered in ALPPS 
candidates. Therefore, I recommend removing the content on other tumor entities and other 
 
 
topics that deviate the content of the paper from the main purpose of the review. The authors 
should expand the manuscript more towards to all ALPPS aspects in CRLM. 
Thank you, we have removed two paragraphs regarding the use of ALPPS for CCA and 
HCC and expanded the section on CRLM 
2. Along with the previous point, I recommend changing the title and keeping the proposed title 
by the editors "Associating Liver Partition and Portal vein ligation for Stage hepatectomy 
(ALPPS) procedure for Colorectal Cancer Liver Metastasis". 
Thank you, we have changed the title to the requested title. 
3. Figure 1 is very informative and presents an excellent summary illustration; however, all 
recommendations that do not exclusively apply to CRLM should be removed (e.g. HCC, CCA). 
Please add under the "STOP" category following points: (i) no upfront chemotherapy, (ii) 
progression under/after neoadjuvant chemotherapy, (iii) unfit for surgery. Please add under the 
"CAUTION" category: (i) symptomatic primary tumors need to be first addressed (primary-first 
approach) before ALPPS can be considered for synchronous CRLM. 
Thank you for these thoughtful suggestions, the figure has been amended as suggested. 
4. The title of figure 1 needs to be "Best-practice recommendations for associating liver partition 
with portal vein ligation for stage hepatectomy (ALPPS) in patients with colorectal liver 
metastases". 
Thank you, the title has been changed as requested. 
5. One of the coauthors of this review is also investigator of the LIGRO trial. A very recently 
accepted paper of this group shows superior survival outcome of the ALPPS compared to TSH 
group. These findings were also presented by the LIGRO group at the 3rd ISLS Meeting in 
Istanbul. The talk entitled "ALPPS improves survival compared with TSH in patients affected of 
CRLM - survival analysis from the randomized controlled trial LIGRO" was presented by Kristina 
Hasselgren. Therefore, I would strongly recommend including the most recent findings of this 
trial in the revised mansucript. 
Indeed since the first writing of this manuscript the seminal results on overall survival 
from the LIGRO trial have been published. The manuscript now reviews extensively the 
findings from the LIGRO trial and includes a figure from these findings. 
6. Although figure 1 is excellent, the review would benefit from additional figures and/or tables. 
An example could be a table summarizing ALPPS studies in patients with CRLM (please see 
doi: 10.1002/jso.25435). 
Thank you, we have included an additional figure which includes a table as well. 
7. Please include reference doi: 10.1016/j.hpb.2018.12.003. 




Reviewer #3: I read the manuscript ID IJS-D-19-01002 with great interest. The authors 
summarized the development of ALPPS with a great descriptive figure. 
I think the manuscript will be vey useful after some minor corrections. 
  
1- Since the title says ALPPS in CRLM, more details of the role of ALPPS in CRLM should be 
included. 
Thank you, we have re-focused the manuscript from one on ALPPS more generally to 
one on ALPPS for CRLM with removal of discussion on its role in other cancers and with 
an expanded discussion on exciting recently published trial data. 
2- A table which summarizes all studies (which are not too many) of ALPPS in CRLM will be 
very useful for the readers. 
Thank you, we have included a table demonstrating the survival following ALPPS for 
contemporary studies (Table 1). 
3- Highlight bullet # 3 and # 4 are same. Please omit one. 
Thank you, these bullets have been reconciled 
4- There is no need to cite reference in the abstract. 
The citation was removed from the abstract, thank you. 
5- Last sentenced in the abstract there is a typo "...of CRLM IS codified.' 
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 Since first described, Associating Liver Partition and Portal Vein Ligation for Staged 
Hepatectomy (ALPPS) has garnered boisterous praise and fervent criticism. Its rapid adoption 
and employment for a variety of indications resulted in high perioperative morbidity and 
mortality. However recent risk stratification, refinement of technique to reduce the impact of 
stage I and progression along the learning curve have resulted in improved outcomes. The first 
randomized trial comparing ALPPS to two stage hepatectomy (TSH) for colorectal liver 
metastases (CRLM) was recently published demonstrating comparable perioperative morbidity 
and mortality with improved resectability following ALPPS. In this review, as ALPPS enters the 
thirteenth year since conception, the current status of this contentious two stage technique is 






Figure 1: (A) LIGRO Trial intermediate clinical and surgical outcomes. (B) Overall survival 
analysis for patients randomized to ALPPS vs. TSH with unresectable colorectal liver 
metastases and insufficient future liver remnant. Median survival estimate 46% vs. 26% (95% CI 
34–59 and 16– 36, respectively; P= 0.028). Reproduced from Hasselgren et. al. Ann. Surg, 
2019 [54,58,59]. Abbreviations: ALPPS; associating liver partition with portal vein ligation for 






















Figure 2: Best-practice recommendations for Associating Liver Partition with Portal Vein 
Ligation for Stage Hepatectomy for Colorectal Liver Metastases. Abbreviations: ALPPS; 




































2014 Schadde [9] Observational  141 76% 63% - - 
2015 Lang [60] Observational  7 - - 64%  
2015 Ratti [53] Observational  12 92% - - - 
2016 Adam [52] Observational  17 - 42%   
2016 Bjӧrnsson [61] Observational 23 83% 59% - - 
2017 Olthof [62] Observational  70 - 62% - - 
2017 Wanis [50] Observational  58 93% 66% 50% - 
2018 Serenari [63] Observational  26 83% - 49% - 
2019 Linecker [64] Observational  213 84% 66% 54% 34% 
2020 Hasselgren [59] RCT 48 83%a 73%a 61%a - 
 
Table 1: Overall Survival after Associating Liver Partition and Portal Vein Ligation for Staged 
Hepatectomy for Colorectal Liver Metastases. (a) Unpublished data from LIGRO trial. 




Year Reference Design Patients  1  year 
Survival 
2  year 
survival 
3  year 
survival 
5  year 
survival 
2014 Schadde  [9] Observational  141 76% 63% - - 
2015 Lang  [60] Observational  7 - - 64%  
2015 Ratti  [53] Observational  12 92% - - - 
2016 Adam  [52] Observational  17 - 42%   
2016 Bjӧrnsson  [61] Observational 23 83% 59% - - 
2017 Olthof  [62] Observational  70 - 62% - - 
2017 Wanis  [50] Observational  58 93% 66% 50% - 
2018 Serenari  [63] Observational  26 83% - 49% - 
2019 Linecker  [64] Observational  213 84% 66% 54% 34% 
2020 Hasselgren  [59] RCT 48 83% a 73% a  61% a  - 
 
Table  1:  Overall  Survival  after  Associating  Liver  Partition  and  Portal  Vein  Ligation  for  Staged 
Hepatectomy  for  Colorectal  Liver  Metastases.  (a)  Unpublished  data  from  LIGRO  trial. 




Figure  1:  (A)  LIGRO  Trial  intermediate  clinical  and  surgical  outcomes.  (B)  Overall  survival 
analysis  for  patients  randomized  to  ALPPS  vs.  TSH  with  unresectable  colorectal  liver 
metastases  and  insufficient  future  liver  remnant.  Median  survival  estimate  46%  vs.  26%  (95%  CI 
34–59  and  16–  36,  respectively;  P=  0.028).  Reproduced  from Hasselgren  et.  al.  Ann.  Surg, 
2019 [54,58,59] .  Abbreviations:  ALPPS;  associating  liver  partition  with  portal  vein  ligation  for 





















Figure  2: Best-practice  recommendations  for  Associating  Liver  Partition  with  Portal  Vein 
Ligation  for  Stage  Hepatectomy  for  Colorectal  Liver  Metastases.  Abbreviations:  ALPPS; 


























● ALPPS has demonstrated excellent ability to achieve resectability compared to portal 
vein embolization (PVE) and two-staged hepatectomy (TSH) in patients with colorectal 
liver metastases (CRLM) and insufficient future liver remnant (FLR). 
● Outcomes with ALPPS for CRLM have improved and are comparable to other major 
hepatectomies. 
● There  is  no  evidence  that  the  enhanced  hypertrophy  generated  by  ALPPS  is 
oncologically inferior to techniques such as PVE or portal vein ligation (PVL). 
● ALPPS is a single tool in a broader armamentarium that should not be overused or 
misused. 
● Patient's colorectal cancer (CRC) biology should be considered when considering 
surgical intervention; poor tumor biology is rarely defeated by herculean surgery. 
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